Rubius Therapeutics, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
6Rubius rapeutics's Business Model
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
About Rubius rapeutics
Website: https://www.rubiustx.com
CEO (Chief Executive Officer): Dr. Laurence A. Turka M.D.
IPO date: 2018-07-18
Contact
Country: US
Address: 399 Binney Street
City: Cambridge
State: MA
Phone: 617 679 9600
Zip Code: 02139
Other
CIK: 0001709401
ISIN: US78116T1034
CUSIP: 78116T103
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
